Patents by Inventor Marvin J. Grubman
Marvin J. Grubman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8906384Abstract: A member of the bovine type III IFN family, boIFN-?3, was identified and characterized. We expressed boIFN-?3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Cattle were inoculated with Ad5-boIFN-?3 followed by intradermolingual or aerosol FMDV challenge. Results demonstrated that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-?3 alone or in combination with IFN-? is able to confer delayed and reduced severity of FMD. Furthermore inoculation with Ad5-boIFN-?3 alone conferred full protection against aerosol challenge for at least 7 days after administration suggesting that type III IFN used in combination with FMD vaccines could fill one of the current gaps in emergency vaccination against FMDV.Type: GrantFiled: December 22, 2010Date of Patent: December 9, 2014Assignee: The United States of America as represented by The Secretary of AgricultureInventors: Teresa B. De Los Santos, James J. Zhu, Fayna Diaz-San Segundo, Marvin J. Grubman, Marla J. Koster
-
Patent number: 8846057Abstract: Previously we have identified a conserved domain (SAP, for SAF-A/B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited.Type: GrantFiled: January 19, 2011Date of Patent: September 30, 2014Assignee: The United States of America, as Represented by the Secretary of AgricultureInventors: Teresa B. De Los Santos, James J. Zhu, Fayna Diaz-San Segundo, Marvin J. Grubman, Marla J. Koster
-
Patent number: 8323663Abstract: The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.Type: GrantFiled: May 8, 2008Date of Patent: December 4, 2012Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Joseph T. Bruder, C. Richter King, Marvin J. Grubman, John G. Neilan
-
Publication number: 20120164171Abstract: Interferons are the first line of defense against viral infections and administration of interferons as biotherapeutics has been demonstrated to be effective in controlling several viral infections. Here we report for the first time the identification and characterization of a member of the bovine type III IFN family, boIFN-?3. We have expressed boIFN-?3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Furthermore, we have tested the efficacy of boIFN-?3 against FMDV in vivo by inoculation of cattle with Ad5-boIFN-?3 followed by intradermolingual or aerosol virus challenge. Our results demonstrate that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-?3 alone or in combination with IFN-? is able to confer delayed and reduced severity of FMD.Type: ApplicationFiled: December 22, 2010Publication date: June 28, 2012Inventors: Teresa B. De Los Santos, James J. Zhu, Fayna Diaz-San Segundo, Marvin J. Grubman, Marla J. Koster
-
Patent number: 8058248Abstract: Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from challenge with virulent foot and mouth disease virus. Co-administration with an effective foot and mouth disease virus vaccine provides protection prior to the development of specific immunity, a feature especially desireable during a FMD outbreak.Type: GrantFiled: April 24, 2002Date of Patent: November 15, 2011Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Marvin J. Grubman, Jarasvech Chinsangaram, Marla Koster, Mauro P. Moraes
-
Publication number: 20110177123Abstract: Previously we have identified a conserved domain (SAP, for SAF-A/B, Acinus, and PIAS) in the foot-and-mouth disease virus (FMDV) leader (L) protein coding region that is required for proper sub-cellular localization and function. Mutation of isoleucine 55 and leucine 58 to alanine (I55A, L58A) within the SAP domain resulted in a viable virus that displayed a mild attenuated phenotype in cell culture, along with altered sub-cellular distribution of L and failure to induce degradation of the transcription factor nuclear factor kappa-B. Here we report that inoculation of swine and cattle with this mutant virus results in the absence of clinical disease, the induction of a significant FMDV-specific neutralizing antibody response, and protection against subsequent homologous virus challenge. Remarkably, swine vaccinated with SAP mutant virus are protected against wild type virus challenge as early as two days post-vaccination suggesting that a strong innate as well as adaptive immunity is elicited.Type: ApplicationFiled: January 19, 2011Publication date: July 21, 2011Inventors: De Los Santos et al., James J. Zhu, Fayna Diaz-San Segundo, Marvin J. Grubman, Marla J. Koster
-
Patent number: 7833533Abstract: Previously, we showed that type I interferon (alpha/beta interferon [IFN-?/?]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 109 PFU of human adenovirus type 5 expressing porcine IFN-? (Ad5-pIFN-?) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-?) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-?, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 108 PFU of Ad5-pIFN-?, low- or high-dose Ad5-pIFN-?, or a combination of Ad5-pIFN-? and low- or high-dose Ad5-pIFN-? and challenged all groups with FMDV 1 day later.Type: GrantFiled: April 24, 2008Date of Patent: November 16, 2010Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Marvin J. Grubman, Marla J. Koster, Mauro Moraes
-
Publication number: 20090269372Abstract: Previously, we showed that type I interferon (alpha/beta interferon [IFN-?/?]) can inhibit foot-and-mouth disease virus (FMDV) replication in cell culture, and swine inoculated with 109 PFU of human adenovirus type 5 expressing porcine IFN-? (Ad5-pIFN-?) were protected when challenged 1 day later. In this study, we found that type II pIFN (pIFN-?) also has antiviral activity against FMDV in cell culture and that, in combination with pIFN-?, it has a synergistic antiviral effect. We also observed that while each IFN alone induced a number of IFN-stimulated genes (ISGs), the combination resulted in a synergistic induction of some ISGs. To extend these studies to susceptible animals, we inoculated groups of swine with a control Ad5, 108 PFU of Ad5-pIFN-?, low- or high-dose Ad5-pIFN-?, or a combination of Ad5-pIFN-? and low- or high-dose Ad5-pIFN-? and challenged all groups with FMDV 1 day later.Type: ApplicationFiled: April 24, 2008Publication date: October 29, 2009Inventors: Marvin J. Grubman, Marla J. Koster
-
Publication number: 20090253185Abstract: The present invention relates to modified poxyiral vectors and to methods of making and using the same. In particular, the invention relates to recombinant avipox that expresses gene products of foot and mouth disease virus (FMDV), and to compositions or vaccines that elicit immune responses directed to FMDV gene products and which can confer protective immunity against infection by FMDV.Type: ApplicationFiled: May 4, 2009Publication date: October 8, 2009Inventors: Robert Nordgren, Sheena May Loosmore, Jean-Christophe Francis Audonnet, Marvin J. Grubman
-
Patent number: 7527960Abstract: The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant avipox that expresses gene products of foot and mouth disease virus (FMDV), and to compositions or vaccines that elicit immune responses directed to FMDV gene products and which can confer protective immunity against infection by FMDV.Type: GrantFiled: April 20, 2005Date of Patent: May 5, 2009Assignee: Merial LimitedInventors: Robert Nordgren, Sheena May Loosmore, Jean-Christophe Francis Audonnet, Marvin J. Grubman
-
Publication number: 20030171314Abstract: Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from challenge with virulent foot and mouth disease virus. Co-administration with an effective foot and mouth disease virus vaccine provides protection prior to the development of specific immunity, a feature especially desireable during a FMD outbreak.Type: ApplicationFiled: April 24, 2002Publication date: September 11, 2003Inventors: Marvin J. Grubman, Jarasvech Chinsangaram, Marla Koster, Mauro P. Moraes
-
Patent number: 5824316Abstract: A foot-and-mouth disease virus has been genetically engineered by deleting the nucleic acid sequence encoding the leader (L) proteinase from an infectious cDNA copy of the viral genome and producing an L proteinase-deleted virus. The L proteinase-deleted viruses are able to assemble and grow in cells in culture, but, since they lack L proteinase, they are less toxic to infected cells within the animal, producing an attenuated infection. The recombinant virus can be formulated into an effective vaccine for the prevention of foot-and-mouth disease.Type: GrantFiled: May 24, 1996Date of Patent: October 20, 1998Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Marvin J. Grubman, Peter W. Mason, Maria Elisa Piccone, Elizabeth Rieder